Is there any facilitated regulatory pathway of drug registration in Taiwan?

刊登日期:2021-10-14  |  點閱次數 : 3692 次 

Taiwan Food and Drug Administration (TFDA) has developed five expedited programs to help to accelerate the application process. Expedited programs include “Abbreviated Review”, “Priority Review”, “Accelerated Approval”, “Breakthrough Therapy” and “Pediatric and Rare Severe Disease Priority Review Voucher Program”.


An applicant should apply for designation in advance. At the time of NDA submission, the applicant should provide the designation letter.


To find further details, please refer to the CDE website: Drugs>New Drug Application (NDA)



上一筆 When will the e-submission system be fully implemented for the new drug registrat
下一筆 If only Class 3 solvents are used in themanufacturing process of active pharmaceu